The present invention relates to a polynucleotide comprising a gene encoding a hook protein and a gene encoding a protein of interest, said protein of interest being either a secretory protein or a cell membrane-anchored protein, wherein: said gene encoding the hook protein is under the control of a first transcription-activating signal, said gene encoding the protein of interest is under the control of a second transcription-activating signal, said second transcription-activating signal allowing a lower rate or frequency of transcription initiation than the first transcription-activating signal, said hook protein is fused to a cellular compartment-retention peptide, and said protein of interest is fused to a hook protein-binding domain

It also related to vectors comprising the polynucleotide, cells comprising the polynucleotide or the vector and compositions comprising the same. It further relates to methods and uses for modulating the secretion or cell membrane-anchorage of a protein of interest, or for preventing and/or treating a disease in a subject in need thereof.

Described herein are compositions and methods of producing glycosylated proteins in vitro and in vivo. The methods include using host cells to produce glycosylated proteins. Also described herein are glycosylated proteins produced using such methods and uses thereof.

The present invention provides compositions comprising an anti-CD7 chimeric activating receptor (CAR) and an anti-CD7 protein expression blocker, and methods of using such compositions in cancer therapy.

Compositions, methods, and uses of recombinant calreticulin protein that is modified to be expressed on the cell surface are presented. Preferably, the recombinant calreticulin protein is presented on the antigen presenting cell surface with a tumor associated protein to increase immunogenicity of the tumor cell in the tumor microenvironment.

[Problem to be Solved] The object of the present invention is to develop a method of regulating a target RNA.

[Solution] There is provided a fusion protein comprising a functional domain which improves the protein expression level from mRNA and a PPR protein which can bind to a target mRNA in an RNA base-selective or RNA base sequence-specific manner.

A peptide comprised of either a binary or a tertiary peptide, the peptide contains at least 4 amino acids and up to a maximum of 16 amino acids, comprised of 2 or 3 different regions, wherein the binary peptides have 2 different regions and the tertiary peptides have 3 different regions; wherein, the peptide can be cleaved by both an animal gut protease and an insect or nematode gut protease.

A method for constructing an metal ion binding motif by identifying an metal ion binding peptide that binds an metal ion with specificity, ascertaining at least a portion of a nucleic acid sequence encoding the metal ion binding peptide, tailoring the nucleic acid sequence encoding the metal ion binding peptide into an metal ion binding site, identifying a host protein and a relevant portion of the nucleic acid sequence of the host protein, operatively linking the tailored nucleic acid sequence encoding the metal ion binding peptide and the host protein nucleic acid sequence into an metal ion binding motif sequence, and expressing metal ion binding motif sequence, in which the nucleic acid sequence encoding the metal ion binding peptide is tailored so as to achieve the metal ion binding motif with a desired specificity for the metal ion. Also, the proteins encoded by the metal ion binding motif sequence as constructed by the method.

Disclosed herein are methods for the large-scale production of a highly thermally stable acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). Additionally, the expression methods disclosed herein can produce ChE preparations consisting of extract or purified forms that can be produced in high amounts and are highly thermally stable. These ChE products can be used in vitro detection, detoxification and decontamination methods.

Provided are methods for the identification of mutant kinases that are resistant to inhibition by a kinase inhibitor. In some embodiments, the methods may be used to assess a test compound or kinase inhibitor for the risk of the development of resistance in vivo, e.g., during clinical administration to treat a disease such as a cancer.

The present invention provides compositions comprising an anti-CD7 chimeric activating receptor (CAR) and an anti-CD7 protein expression blocker, and methods of using such compositions in cancer therapy.